Litigation Details for Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC (D. Del. 2015)

Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC (D. Del. 2015)

Docket		Date Filed	2015-10-23
Court	District Court, D. Delaware	Date Terminated	2016-01-12
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,503,894; 8,729,057; 8,741,881; 8,754,070; 8,759,329; 9,125,816; 9,132,089
Link to Docket	External link to docket

Details for Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-23				External link to document
2015-10-23	11		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,503,894; 8,729,057; 8,741,881; 8,754,070…2015 12 January 2016 1:15-cv-00964 830 Patent None District Court, D. Delaware	External link to document
2015-10-23	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,503,894; 8,729,057; 8,741,881; 8,754,070…2015 12 January 2016 1:15-cv-00964 830 Patent None District Court, D. Delaware	External link to document

Unimed Pharmaceuticals v. Amneal Pharmaceuticals: Litigation Summary and Patent Analysis

Last updated: August 18, 2026

Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC, No. 1:15-cv-00964, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Amneal’s proposed generic version of AndroGel 1.62%, a topical testosterone replacement product. Unimed, an AbbVie-associated company, sued after receiving notice of Amneal’s abbreviated new drug application, or ANDA, and asserted patents covering testosterone-gel formulations and their use.

The case appears to have ended through a settlement-related dismissal rather than a reported merits judgment. The public record does not establish a judicial finding that Amneal’s ANDA product infringed or that the asserted patent claims were valid.

What drug was at issue in Unimed Pharmaceuticals v. Amneal?

The litigation concerned AndroGel 1.62%, a prescription testosterone gel marketed for testosterone replacement therapy in adult males with deficient or absent endogenous testosterone.

Item	Information
Brand	AndroGel 1.62%
Active ingredient	Testosterone
Dosage form	Topical transdermal gel
Reference sponsor	AbbVie group, including Unimed Pharmaceuticals
Regulatory pathway	Abbreviated New Drug Application under the Hatch-Waxman Act
Defendant’s product	Amneal’s proposed generic testosterone gel
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00964
Case type	ANDA patent litigation
Procedural outcome	Settlement-related dismissal; no reported trial judgment identified

AndroGel 1.62% is distinct from earlier testosterone gel products, including AndroGel 1%, because it uses a different concentration and product design. The 1.62% formulation was developed to provide testosterone delivery through application to specified skin sites, principally the shoulders and upper arms.

What patents protected AndroGel 1.62% in the Amneal case?

The central patent associated with the AndroGel 1.62% patent estate was U.S. Patent No. 8,435,944. The patent was directed to testosterone gel formulations and methods of treating testosterone deficiency.

U.S. Patent No. 8,435,944

Field	Information
Patent number	US 8,435,944
General subject matter	Testosterone gel formulations and methods of use
Patent holder or affiliated owner	AbbVie/Unimed-related interests
Product association	AndroGel 1.62%
Orange Book relevance	Listed in connection with AndroGel 1.62% during the relevant period
Expected expiration	2027, subject to applicable patent-term adjustments or extensions
Litigation role	Principal patent associated with generic challenges to AndroGel 1.62%

The patent estate also included earlier testosterone-gel intellectual property, including U.S. Patent No. 6,503,894, which covered aspects of testosterone gel technology and had an earlier expiration date. The commercial importance of the ’894 patent was reduced by the time of the Amneal litigation because its ordinary patent term was approaching expiration.

The precise patent claims litigated against Amneal should be determined from the complaint, infringement contentions, and the relevant docket filings. The public procedural record is clearer on the existence of the ANDA dispute and its resolution than on a final claim-by-claim adjudication.

What was the legal basis for the Unimed v. Amneal lawsuit?

Unimed filed the action after Amneal submitted an ANDA seeking FDA approval to market a generic testosterone gel. The lawsuit was a conventional Hatch-Waxman case triggered by an Abbreviated New Drug Application and a Paragraph IV certification.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The filing of a patent-infringement action within the statutory period generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the stay is shortened or otherwise terminated.

The principal legal issues would have included:

1. Whether Amneal’s proposed formulation fell within the asserted composition claims.
2. Whether Amneal’s proposed labeling induced infringement of method-of-use claims.
3. Whether the asserted patent claims were invalid for obviousness.
4. Whether the patent claims were anticipated by earlier testosterone formulations.
5. Whether the claims were adequately supported and definite.
6. Whether any asserted patent remained enforceable against the proposed generic product.

Because the case did not produce a reported merits decision, the docket does not provide a judicial resolution of those issues.

Did Amneal file a Paragraph IV challenge to AndroGel?

The case was an ANDA dispute, and the litigation posture indicates that Amneal’s regulatory filing included a patent certification sufficient to support an infringement action. In practical terms, Unimed treated Amneal’s ANDA as an at-risk challenge to the AndroGel 1.62% patent position.

A Paragraph IV challenge would have allowed Amneal to seek FDA approval before expiration of every relevant patent, subject to the statutory litigation stay. It also created commercial leverage for both parties:

• Unimed could preserve the branded product’s exclusivity through litigation.
• Amneal could seek an earlier generic launch date through settlement.
• The parties could allocate commercial risk without waiting for a final trial judgment.
• FDA approval timing remained separate from the court’s patent analysis.

The public record does not establish that Amneal obtained a court ruling authorizing an immediate launch.

What was the litigation outcome?

The case ended without a reported infringement trial, validity judgment, or appellate decision. The docket reflects a settlement-related resolution and dismissal.

That outcome has several consequences:

• No binding claim construction opinion appears to have established the scope of the asserted claims against Amneal.
• No court held the patent claims valid or invalid in this specific action.
• No court determined that Amneal’s ANDA product infringed.
• The settlement terms, including any agreed launch date, licensing provisions, or payment terms, are not established by the publicly available dismissal record.
• The dismissal should not be treated as confirmation that the patent estate was enforceable through its full nominal expiration period.

In pharmaceutical patent litigation, a dismissal following settlement often indicates that the parties reached a negotiated arrangement concerning generic entry, but the dismissal alone does not disclose whether entry was permitted before patent expiration or whether other commercial conditions applied.

How strong was the AndroGel 1.62% patent estate?

The estate had meaningful commercial value but material litigation risk.

Factors supporting patent strength

The AndroGel 1.62% estate had several advantages:

• It covered a commercially important approved testosterone product.
• The ’944 patent extended beyond the expiration of earlier testosterone-gel patents.
• Product-specific formulation and method-of-use claims can create a barrier to simple formulation substitution.
• Orange Book listing increased the litigation leverage available to the brand owner.
• The product had an established regulatory and commercial position before generic competition intensified.

Factors weakening the estate

The estate also faced significant vulnerabilities:

• Testosterone gels were part of a technically mature field.
• Earlier testosterone delivery systems created prior-art pressure.
• Obviousness arguments were likely to focus on concentration selection, excipient choice, absorption targets, and application-site instructions.
• A generic applicant could design around certain formulation limitations.
• Method-of-use claims may be vulnerable if the generic label omits or narrows the patented indication or instructions.
• A settlement could permit generic entry well before the nominal expiration of the longest patent.

The ultimate commercial strength of the estate therefore depended less on the expiration date alone than on the settlement terms and the ability of generic manufacturers to avoid infringement through formulation or labeling changes.

What was the FDA and Orange Book status?

AndroGel 1.62% was an FDA-approved testosterone replacement product. Its patent information was listed in the FDA Orange Book during the period relevant to the litigation.

The Orange Book listing had three important effects:

1. It gave the reference sponsor a basis for suing after an ANDA Paragraph IV notice.
2. It created the statutory 30-month approval stay after timely patent litigation.
3. It informed generic applicants which listed patents had to be addressed in the ANDA.

Orange Book listing does not mean that a listed patent is valid or infringed. FDA listing is an administrative patent-information function, while validity, enforceability, and infringement are judicial questions.

The regulatory exclusivity profile was separate from patent protection. AndroGel 1.62% did not receive the type of biologic exclusivity associated with reference biologics, and biosimilar rules were not applicable. Testosterone is a small-molecule drug regulated through the ANDA pathway.

Were biosimilars a risk in this case?

No. Biosimilar risk was not the relevant competitive threat.

Testosterone is a chemically defined small-molecule active ingredient. Generic testosterone gel products are approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not under the biosimilar pathway in section 351(k) of the Public Health Service Act.

The relevant risks were:

• ANDA Paragraph IV challenges.
• Formulation design-arounds.
• Labeling carve-outs.
• Generic products with different concentrations or application instructions.
• Authorized-generic competition.
• Post-expiration multi-source generic entry.

What generic launch scenarios did the settlement create?

The dismissal does not publicly establish the precise Amneal launch date. The principal scenarios in an AndroGel settlement were:

Scenario	Commercial effect
Entry at patent expiration	Preserves branded sales until the longest enforceable patent expires
Early licensed entry	Allows Amneal to launch before nominal patent expiration under agreed conditions
Royalty-bearing entry	Permits launch while transferring part of generic revenue to the patent owner
Authorized-generic arrangement	Allows brand-affiliated supply or distribution before broad generic competition
Delayed entry tied to another generic	Coordinates market entry and limits first-wave erosion
No immediate launch	Maintains the settlement’s value if regulatory or manufacturing issues remain unresolved

A settlement can be economically favorable to a generic applicant even when it does not eliminate every asserted patent. Conversely, an early-entry agreement can materially reduce the brand’s remaining revenue exposure while avoiding litigation uncertainty.

What patent litigation affected AndroGel 1.62% beyond Amneal?

AndroGel 1.62% was subject to broader generic competition and patent litigation involving multiple ANDA applicants. Related cases included actions against other generic manufacturers, including Teva and Actavis-related entities.

A significant judicial development in the broader AndroGel patent litigation was the Federal Circuit’s decision in AbbVie Inc. v. Teva Pharmaceuticals USA, Inc., which addressed the validity of claims associated with testosterone-gel technology. That decision contributed to the risk analysis surrounding the asserted patent estate and showed that nominal Orange Book expiration dates did not guarantee enforceable market exclusivity. (AbbVie Inc. v. Teva Pharmaceuticals USA, Inc., 2014)

The broader litigation landscape matters because a patent owner generally cannot assess one ANDA challenge in isolation. A validity ruling against a related patent, a favorable claim construction, or a settlement with an earlier-filing generic can affect the bargaining position in later cases.

How does the AndroGel patent estate compare with generic competition?

The key competitive distinction was between patent protection and product substitution.

A generic applicant could challenge the patents directly, but it could also seek regulatory approval with a product that differed in concentration, excipient profile, application site, or labeling. If those differences avoided the asserted claims while satisfying FDA requirements, the generic could reduce patent exposure without defeating the entire brand patent estate.

For Unimed and its affiliates, this created a layered risk:

• The earliest patents protected older testosterone-gel technology but expired sooner.
• Later patents protected the commercial 1.62% product and extended the nominal exclusivity period.
• Method claims depended on the approved label and the generic’s proposed instructions.
• Formulation claims depended on the precise composition of the ANDA product.
• Settlement terms determined the practical launch date more directly than the patent expiration date.

What was the revenue exposure from generic entry?

AndroGel was a major testosterone-replacement product, but revenue exposure depended on the concentration and product segment. Generic entry typically produces rapid price erosion in small-molecule markets, although topical gels can experience slower substitution than oral tablets because of manufacturing complexity, patient familiarity, prescriber behavior, and payer preferences.

The principal revenue risks were:

• Loss of exclusivity for the 1.62% product.
• Conversion of prescriptions to lower-priced generic testosterone gel.
• Formulary pressure from pharmacy-benefit managers.
• Price reductions required to retain branded market share.
• Competition from other testosterone delivery systems, including injections, patches, and oral products.
• Authorized-generic or limited-launch strategies that reduce the impact of the first entrant.

No public settlement record identified in the case establishes the percentage of sales allocated to Amneal, any royalty, or a guaranteed launch date. Those terms should not be inferred from the dismissal alone.

Key Takeaways

• Unimed Pharmaceuticals v. Amneal Pharmaceuticals, No. 1:15-cv-00964, was a Delaware Hatch-Waxman action involving Amneal’s proposed generic AndroGel 1.62%.
• The dispute centered on testosterone-gel formulation and method-of-use patent rights associated with U.S. Patent No. 8,435,944 and related AndroGel intellectual property.
• The case ended through a settlement-related dismissal rather than a reported trial judgment.
• The public docket does not establish a finding of infringement, validity, or invalidity against Amneal.
• Testosterone is a small-molecule drug, so biosimilar regulation was not relevant.
• Orange Book listing created the statutory framework for the patent suit and potential 30-month FDA approval stay.
• The commercial result depended on confidential settlement terms, including any agreed generic launch date or license.
• The broader AndroGel litigation demonstrated material obviousness and enforceability risk despite the existence of later-expiring patents.

FAQs

When did the AndroGel 1.62% patent expire?

The principal ’944 patent associated with AndroGel 1.62% had a nominal expiration in 2027, subject to applicable patent-term calculations. Earlier testosterone-gel patents, including U.S. Patent No. 6,503,894, expired earlier.

Was Amneal allowed to launch generic testosterone gel?

The public dismissal record does not establish the exact launch terms agreed between Unimed and Amneal. It shows that the case ended without a reported merits judgment.

Did the Unimed v. Amneal case involve a biologic?

No. The product was testosterone, a small-molecule drug regulated through the ANDA pathway.

Did the lawsuit challenge the FDA approval of AndroGel?

No. The case was a patent dispute triggered by Amneal’s ANDA. FDA approval and patent enforceability are separate issues.

Can a generic testosterone gel avoid AndroGel patents?

Potentially. A generic applicant may reduce infringement exposure through differences in formulation, concentration, application site, or labeling, subject to FDA requirements and the specific language of the asserted claims.